Merck KGaA (OTCMKTS:MKGAY) has earned an average rating of “Hold” from the nine brokerages that are currently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and three have assigned a buy recommendation to the company.
MKGAY has been the topic of a number of recent analyst reports. UBS Group lowered shares of Merck KGaA from a “neutral” rating to a “sell” rating in a research report on Tuesday. DZ Bank downgraded shares of Merck KGaA from a “buy” rating to a “hold” rating in a research note on Friday, July 9th.
Shares of OTCMKTS MKGAY opened at $38.36 on Friday. The firm’s 50-day moving average price is $38.36 and its 200-day moving average price is $38.36. Merck KGaA has a 12-month low of $32.53 and a 12-month high of $42.02.
Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility.
Recommended Story: How Does the Quiet Period Work?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.